Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

21 mars 2025 07h00 HE | Source: Rapport Therapeutics, Inc.

Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting

Rapport will present two encore posters at the American Academy of Neurology Annual Mtg - data on RAP-219, which is in current Ph2a trial in focal epilepsy
11 mars 2025 07h00 HE | Source: Rapport Therapeutics, Inc.

Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
09 janv. 2025 09h12 HE | Source: Rapport Therapeutics, Inc.

CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders

Rapport announced new data from its Phase 1 PET and MAD-2 trials for RAP-219 being studied as a novel precision medicine for patients with CNS disorders.
09 janv. 2025 07h00 HE | Source: Rapport Therapeutics, Inc.

Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders

Rapport announced new data from its Phase 1 PET and MAD-2 trials for RAP-219 being studied as a novel precision medicine for patients with CNS disorders.